Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast ; volume:11 ; number:4 ; day:29 ; month:9 ; year:2023 ; pages:411-418 ; date:12.2023
Oncology and Therapy ; 11, Heft 4 (29.9.2023), 411-418, 12.2023

Creator: Dong, Brian
Lusen, Rita
Chick, Ella
Kline, Lisa

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40487-023-00237-4

URN: urn:nbn:de:101:1-2024020714500552257618

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Dong, Brian
Lusen, Rita
Chick, Ella
Kline, Lisa
SpringerLink (Online service)

Other Objects (12)

Aufsatzsammlung

Aromatase inhibitors

Aufsatzsammlung

Aromatase inhibitors

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Aromatase inhibitors in post-menopausal endometriosis

CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

CDK4/6-Inhibitor Palbociclib und PARP-Inhibitor Talazoparib im Fokus : Behandlung von HR+/HER2- metastasiertem Brustkrebs : 4 Kasuistiken aus der Praxis

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

Use of aromatase inhibitors in practice of gynecology

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Aufsatzsammlung

Aromatase inhibitors

Aufsatzsammlung

Aromatase inhibitors

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Aromatase inhibitors in post-menopausal endometriosis

CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

CDK4/6-Inhibitor Palbociclib und PARP-Inhibitor Talazoparib im Fokus : Behandlung von HR+/HER2- metastasiertem Brustkrebs : 4 Kasuistiken aus der Praxis

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

Use of aromatase inhibitors in practice of gynecology

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Aufsatzsammlung

Aromatase inhibitors

Aufsatzsammlung

Aromatase inhibitors

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Aromatase inhibitors in post-menopausal endometriosis

CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

CDK4/6-Inhibitor Palbociclib und PARP-Inhibitor Talazoparib im Fokus : Behandlung von HR+/HER2- metastasiertem Brustkrebs : 4 Kasuistiken aus der Praxis

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

Use of aromatase inhibitors in practice of gynecology

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Shared Decision-Making on Using a CDK4/6 Inhibitor plus an Aromatase Inhibitor for HR+/HER2− Metastatic Breast Cancer: A Podcast

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Aromatase inhibitors

Aromatase inhibitors

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Aromatase inhibitors in post-menopausal endometriosis

CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

CDK4/6-Inhibitor Palbociclib und PARP-Inhibitor Talazoparib im Fokus : Behandlung von HR+/HER2- metastasiertem Brustkrebs : 4 Kasuistiken aus der Praxis

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

Use of aromatase inhibitors in practice of gynecology

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Aromatase inhibitors

Aromatase inhibitors

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Aromatase inhibitors in post-menopausal endometriosis

CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

CDK4/6-Inhibitor Palbociclib und PARP-Inhibitor Talazoparib im Fokus : Behandlung von HR+/HER2- metastasiertem Brustkrebs : 4 Kasuistiken aus der Praxis

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

Use of aromatase inhibitors in practice of gynecology

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Aromatase inhibitors

Aromatase inhibitors

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Aromatase inhibitors in post-menopausal endometriosis

CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

CDK4/6-Inhibitor Palbociclib und PARP-Inhibitor Talazoparib im Fokus : Behandlung von HR+/HER2- metastasiertem Brustkrebs : 4 Kasuistiken aus der Praxis

Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede

Use of aromatase inhibitors in practice of gynecology

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Related objects

Reset password